OBJECTIVES: Advanced heart failure (HF) is a leading cause of death in developed countries. One to two percent of the French population is affected by this disease. It also causes a substantial economic burden on society and cost 1.6 billion euros per year in France.  Usually, cardiac transplantation is the most effective treatment. However, because of a limited donor organ supply, innovative technics as left ventricular assist devices (LVAD) were developed for over 10 years. This study aims to assess the medical and economic consequences of LVAD in adults with advanced HF in France during one year after LVAD implantation. METHODS: The primary medical outcome was the discharge to the patient’s home. Secondary medical outcomes were defined as final situation of patient, survival, dependence and quality of life (QOL) assessed with the SF-36 and the Minnesota QOL questionnaires. This prospective economic analysis adopted the healthcare payer’s perspective and took into account direct medical and non-medical costs. RESULTS: Among the 55 patients included, 37 were discharged at home during an average of 140 days. At one year, 23 patients were still on device and spent 238 days at home, 15 were transplanted and spent 132 days at home and 17 were died and spent 13 days at home. The mean total cost per implanted patient was 164,154±37,104€. Costs drivers were the device (58%) and initial hospitalization (30%). The cost of at home care was 6,084±6,738€ accounting for only 4% of total cost. According to the healthcare payer’s perspective, one day spent at home costs 44€. Survival, QOL and dependence analyses are being processed. CONCLUSIONS: Continuous- flows LVAD represent a costly strategy in the HF treatment but allow the patient to be discharged at home instead of awaiting heart transplantation at hospital.